Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)
Completed · Phase 2
Conditions studied: Relapsed/Refractory Mantle Cell Lymphoma
In brief
The goal of this clinical study is to test how well the study drug, brexucabtagene autoleucel (KTE-X19), works in participants with relapsed/refractory (r/r) mantle cell lymphoma (MCL).
Key facts
- Study ID
- NCT02601313
- Run by
- Kite, A Gilead Company
- People needed
- 105
- Starts
- 2015-11-09
- Expected to finish
- 2023-09-22
- Last updated by the study team
- 2026-03-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Banner MD Anderson — Gilbert, Arizona, United States
- City of Hope — Duarte, California, United States
- University California Los Angeles (UCLA) — Santa Monica, California, United States
- Stanford University — Stanford, California, United States
- Sarah Cannon — Denver, Colorado, United States
- University of Miami — Miami, Florida, United States
- H Lee Moffitt Cancer Center — Tampa, Florida, United States
- Winship Cancer Institute of Emory University — Atlanta, Georgia, United States
- University of Chicago — Chicago, Illinois, United States
- Loyola University Chicago — Maywood, Illinois, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Barbara Ann Karmanos Cancer Institute — Detroit, Michigan, United States
- Hackensack University Medical Center — Hackensack, New Jersey, United States
- University of Rochester Medical Center — Rochester, New York, United States
- Duke University Medical Center — Durham, North Carolina, United States
- Cleveland Clinic Foundation — Cleveland, Ohio, United States
- Ohio State University — Columbus, Ohio, United States
- Robert W. Franz Cancer Research Center — Portland, Oregon, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Vanderbilt University Medical Center — Nashville, Tennessee, United States
- Baylor Charles A. Sammons Cancer Center — Dallas, Texas, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- Swedish Cancer Institute — Seattle, Washington, United States
- Centre Hospitalier Universitaire (CHU) — Bordeaux, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.